CEFALI; Eugenio A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for CEFALI; Eugenio A..The latest application filed is for "1-methylnicotinamide for the treatment of diseases associated with c-reactive protein".

Company Profile

0.5.9

CEFALI; Eugenio A. - Fort Lauderdale FL
Cefali; Eugenio A. - Lauderhill FL
Cefali; Eugenio A. - Plantation FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
1-Methylnicotinamide for the Treatment of Diseases Associated With C-Reactive Protein App 20190282560 - Palka; Konrad ; et al.	2019-09-19
Methods For Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics App 20130005779 - Cefali; Eugenio A. ; et al.	2013-01-03
Methods For Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical Characteristics App 20120202855 - Cefali; Eugenio A. ; et al.	2012-08-09
Intermediate Release Nicotinic Acid Compositions For Treating Hyperlipidemia Which Exhibit An In Vivo Stair-stepped Absorption Curve App 20120157685 - Cefali; Eugenio A. ; et al.	2012-06-21
Intermediate Release Nicotinic Acid Compositions For Treating Hyperlipidemia Which Exhibit An In Vivo Stair-stepped Absorption Curve App 20100240899 - Cefali; Eugenio A. ; et al.	2010-09-23
Intermediate Release Nicotinic Acid Compositions For Treating Hyperlipidemia Which Exhibit an In Vivo Stair-Stepped Absorption Curve App 20090054499 - Cefali; Eugenio A.	2009-02-26
Intermediate release nicotinic acid compositions for treating hyperlipidemia Grant 6,818,229 - Cefali , et al. November 16, 2	2004-11-16
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics Grant 6,746,691 - Cefali June 8, 2	2004-06-08
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia Grant 6,676,967 - Cefali , et al. January 13, 2	2004-01-13
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics App 20030161880 - Cefali, Eugenio A.	2003-08-28
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics App 20030157153 - Cefali, Eugenio A.	2003-08-21
Intermediate Release Nicotinic Acid Compositions For Treating Hyperlipidemia Having Unique Biopharmaceutical Characteristics App 20010014338 - CEFALI, EUGENIO A.	2001-08-16
Long acting diltiazem formulation Grant 5,000,962 - Sangekar , et al. March 19, 1	1991-03-19
Immediate release diltiazem formulation Grant 4,992,277 - Sangekar , et al. February 12, 1	1991-02-12

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.